Skip to main content
2025 PharmSci 360 Main banner
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.

Sanjeev Thohan, PhD

CEO
SARx Consulting
LA JOLLA, California

Sanjeev is the President of SARx Consulting, bringing over 30 years of pharmaceutical industry experience, excels in Fractional Leadership for R&D. As Chief Scientific Officer for Alnair Therapeutics, Arise Biopharma, and LatentSpace Therapeutics, he leads initiatives in lead optimization, IND filings, and clinical trial design. Holding an MS and PhD in Pharmacology and Toxicology, his expertise spans interspecies drug metabolism, bioactivation, and systems toxicology.
He has contributed to 42 successful INDs across diverse therapeutic areas and played key roles in two IPOs. His work at organizations such as Walter Reed, Covance, AstraZeneca, Viropharma, Exelixis, Novartis (NIBR), Phoenix Molecular Designs, and Kinnate has resulted in numerous clinical successes, particularly in oncology. His achievements include the development and launch of Rifaximin, Cabozatinib, Cobimetinib, Tafenoquine, Scemblix, Tecovirimat, Gvoke, and Darovasertib.
Beyond consulting, Sanjeev mentors startups, raises funds, and serves on multiple Scientific Advisory Boards, including NIH/NCI collaborations (Centers for Advancing Innovation) and initiatives such as Founders Corner. His advisory roles span biotech companies including Aliri, Arise Bio, Axiom Bio, Cogentis Therapeutics, Formation Venture Engineering, LatentSpace Therapeutics, Phoenix Molecular Designs, and RanTran Bio, driving innovation across therapeutic fields.

Disclosure information not submitted.

Presentation(s):